Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

terminated133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

NCT04176497
withdrawnphase_2

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

NCT04243941
withdrawnphase_2

Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

NCT02810886

Clinical Trials (3)

Showing 3 of 3 trials
NCT04176497Phase 2

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Terminated
NCT04243941Phase 2

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Withdrawn
NCT02810886Phase 2

Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3